"hair can be wiped away. Previously called ""Neet,"" the hair removal product was manufactured by Hannibal Pharmaceutical Company and registered as a US trademark in 1919 in Canada and in 1922 in the US. The trademark for Neet was then picked up by the American Home Products Corporation in 1958. Neet was then transferred to its current holder, Reckitt Benckiser (then called Reckitt & Colman (Overseas) Ltd.). The Veet name was established in 1922 in the UK. The name was used in some European countries, but was not used universally. For example, while the product was sold as Veet in"
"food ingredients (including sugar, wheat, and oil), food, logistics, and biotechnology (including MSG, lysine), processed food and animal feed. It has since expanded globally with offices in China, the U.S., the Philippines, Indonesia, Vietnam, Brazil, Australia, Japan, Russia and Singapore. CJ was recently reported to be in talks with the US Corporation Dendreon who is in trials with a cancer vaccine called Provenge. CJ CheilJedang CJ Cheil Jedang is a South Korean food company based in Seoul that manufactures food ingredients, food, pharmaceuticals and biotechnology. Its brands include Beksul, Bibigo, CJ Hat Kimchi, DASIDA and Haechandle. CJ Cheil Jedang was"
"Vanish and Cillit Bang. It went public in 1997. Reckitt and Sons started in 1840 when Isaac Reckitt rented a starch mill in Hull, England. He diversified into other household products and after his death in 1862, the business passed to his three sons. In 1886, Reckitt opened its first overseas business in Australia. The firm was first listed on the London Stock Exchange in 1888. Harpic Lavatory Cleaners was acquired in 1932, and that same year, Dettol was launched. In 1938 Reckitt & Sons merged with J. & J. Colman, which had been founded in 1814 when Jeremiah Colman"
"well as drug targeting Desmocollin. Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D and Mycobutol Cadila Pharmaceuticals Cadila Pharmaceuticals is a multinational research based pharmaceutical group in India with more than 5 decades of experience in providing high-quality affordable products. Company's integrated operations covers entire gamut from manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Cadila Pharmaceuticals manufacturing facilities are approved by most stringent International bodies like WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. International operation of Cadila Pharmaceuticals is spread across 58 countries"
"that the company had been using for over a decade an Employee Benefit Trust, avoiding paying income tax for its UK staff. In 2018, The Dispute Settlement and Sanctions Committee of CRE, the French Energy Regulatory Commission, fines VITOL S.A. € 5 million for engaging in market manipulation on the French Southern virtual Gas Trading Point (“PEG Sud”) between 1 June 2013 and 31 March 2014. Vitol is appealing this decision. Vitol The Vitol Group is a global energy and commodity trading company that was founded in Rotterdam in 1966 by Henk Viëtor and Jacques Detiger. Though physical trading, logistics"
"Sipuleucel-T Sipuleucel-T (APC8015, trade name Provenge), developed by Dendreon Corporation, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is a personalized treatment that works by programming each patient's immune system to seek out cancer and attack it as if it were foreign. While referred to as a therapeutic vaccine rather than a preventive vaccine that prevents infectious disease, sipuleucel-T is instead an immunostimulant. On February 20, 2015, Valeant Pharmaceuticals received approval to purchase all Dendreon assets (including Provenge). The treatment cost $93,000 at FDA approval, rising to over $100,000 in 2014. A course of treatment consists of three"
"outside the company. In 1964 – Contacts between ""Teva"" company and other companies were developed. These included contacts with ""Sintex Company"" from Mexico, ""Schering Plough"" and others. ▪Optalgin - A product for reducing temperature and for pain relief. The product name ""Optalgin"" as given by Dr. Friedländer was derived from the two words: ""Optimum"" and ""Analgesic"". ▪Bitupal - Compounds intended for treating various dermatological skin diseases that were administered as liquid, ointment and cream, such as Leuko-Bitupal- Cordelta (L.B.C) cream. Bitupal products were produced from bitumen (asphaltite) rocks that were removed from the Dead Sea. In 1959 - The Bitupal"
"Seattle Genetics Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. The companys' flagship product Adcetris (Brentuximab vedotin) is commercially available for four indications in more"
"Design Group[13] · Spinal MetRX · Starr Life Sciences[14] · Vytrace · Wright Therapy Products[15] Therapeutics: · ATRP Solutions[16] · Biomed Research & Technologies · Cognition Therapeutics[17] · Complexa[18] · Knopp Biosciences[19] · Launchcyte[20] · Lipella Pharmaceuticals[1] · LSEC ----[1] <nowiki>http://www.lipella.com/</nowiki> ----[1] <nowiki>http://biosafe.com/</nowiki> [2] <nowiki>http://www.carmellrx.com/</nowiki> [3] <nowiki>http://www.chemdaq.com/</nowiki> [4] <nowiki>http://www.circadiance.com/</nowiki> [5] <nowiki>http://www.coheramedical.com/</nowiki> [6] <nowiki>http://www.flexicath.com/</nowiki> [7] <nowiki>http://www.medrobotics.com/</nowiki> [8] <nowiki>http://www.neuro-kinetics.com/</nowiki> [9] <nowiki>http://quantumops.com/</nowiki> [10] <nowiki>http://regearlife.com/</nowiki> [11] <nowiki>http://rinovum.com/</nowiki> [12] <nowiki>http://rubitection.com/</nowiki> [13] <nowiki>http://www.separationdesign.com/</nowiki> [14] <nowiki>http://www.starrlifesciences.com/</nowiki> [15] <nowiki>http://www.wrighttherapy.com/</nowiki> [16] <nowiki>http://www.atrpsolutions.com/</nowiki> [17] <nowiki>http://www.cogrx.com/</nowiki> [18] <nowiki>http://www.complexarx.com/</nowiki> [19] <nowiki>http://www.knoppneurosciences.com/</nowiki> [20] <nowiki>http://launchcyte.com/</nowiki> ----[1] <nowiki>http://www.cernostics.com/</nowiki> [2] <nowiki>http://intelomed.com/</nowiki> [3] <nowiki>http://www.redpathip.com/</nowiki> [4] <nowiki>http://www.betterbodyimage.com/story.php</nowiki> [5] <nowiki>http://blenderhouse.com/home/</nowiki> [6] <nowiki>http://www.brainstage.com/</nowiki> [7] <nowiki>http://www.caliberindia.com/</nowiki> [8] <nowiki>http://www.hability.net/index.php</nowiki> [9] <nowiki>http://www.hmsinc.com/</nowiki> [10]"
"clinical studies for its RESOLVE device, an in-office treatment for chronic sinusitis, designed to be an alternative to surgery and oral steroid pills. Intersect ENT Intersect ENT () is a publicly traded health care equipment company based in Menlo Park, California. It manufactures drug-delivery devices used by Ear, Nose & Throat (ENT) clinicians in the treatment of sinusitis. Intersect ENT is best known for developing the first bioabsorbable drug-eluting sinus stent PROPEL, which delivers anti-inflammatory medication directly to the sinuses. The company holds over 20 issued patents in the United States and more than 80 patents and patent applications worldwide."
"Dimetapp Dimetapp is a brand of over-the-counter cold and allergy medicines manufactured by Pfizer (formerly Wyeth). At one point, Dimetapp as a household word referred to a single combination preparation marketed to relieve symptoms of the common cold, containing brompheniramine (an antihistamine) and phenylephrine (decongestant replacing the formerly used pseudoephedrine, which itself replaced phenylpropanolamine). Variants were created, including Dimetapp DM with the addition of dextromethorphan (an antitussive or cough suppressant). Dimetapp Elixir and Colour Free Elixir are intended to relieve nasal congestion, runny nose, itchy watery eyes and sneezing, whereas Dimetapp DM and Dimetapp DM Colour Free Elixir are intended"
"Dendreon Dendreon is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66%"
"Intersect ENT Intersect ENT () is a publicly traded health care equipment company based in Menlo Park, California. It manufactures drug-delivery devices used by Ear, Nose & Throat (ENT) clinicians in the treatment of sinusitis. Intersect ENT is best known for developing the first bioabsorbable drug-eluting sinus stent PROPEL, which delivers anti-inflammatory medication directly to the sinuses. The company holds over 20 issued patents in the United States and more than 80 patents and patent applications worldwide. The company was named on the Forbes list of ""America's Most Promising Companies"" and was also on the ""Fierce 15"" list of ""Most"
"the trade name Tridesilon by Dome Laboratories in 1970. Since the discovery in the United States, several other countries have introduced different brand names of desonide, including Italy, Spain, United Kingdom, and Germany. The FDA first approved Connetics Corporation’s Verdeso Foam® on September 16, 2006. Just shortly after, the FDA approved SkinMedica Inc.’s Desonate® hydrogel delivery vehicle on October 20, 2006. Desonate® gel is currently manufactured by Bayer HealthCare Pharmaceuticals Inc. in Whippany, NJ. DesOwen® creams, ointments, and lotions are currently manufactured by DPT Laboratories, Ltd. in San Antonio Texas and is marketed by Galderma Laboratories. Other suppliers for the"
"to treat memory and balance problems. It remains one of UCB's key products. At this time, UCB was a company focusing on three core areas: pharmaceuticals, chemicals and films. The success of ""Nootropil"" made it possible for UCB to build a modern pharmaceutical site in Braine-l'Alleud, south of Brussels. There, UCB developed ""Zyrtec"" (cetirizine), a blockbuster antihistamine. Other important products have followed including ""Keppra"" (levetiracetam), ""Xyzal"" (levocetirizine), and ""Cimzia"" (certolizumab pegol), which was acquired through the acquisition of Celltech. At the end of 2002, the chemicals and films divisions were merged and UCB added the resins, additives and adhesives activities"
"Ceragenix Pharmaceuticals Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Denver, Colorado that develops prescription therapies based on a platform of proprietary surface active technologies—skin Barrier Repair Technology (BRT) and Cerageninis, a new class of broad spectrum anti-infectives. The company discovers, develops and commercializes anti-infective drugs based on its proprietary class of compounds, Ceragenins. Active against a range of gram positive and gram negative bacteria, these agents are being developed as anti-infective medical device coatings and as therapeutics for antibiotic-resistant organisms. Ceragenix developed EpiCeram. It is a topical non-steroidal skin care cream based on the research of Peter Elias"
"Vitol The Vitol Group is a global energy and commodity trading company that was founded in Rotterdam in 1966 by Henk Viëtor and Jacques Detiger. Though physical trading, logistics and distribution are at the core of the business, these are complemented by refining, shipping, terminals, exploration and production, power generation, mining and retail businesses. Vitol has 40 offices worldwide and its largest operations are in Geneva, Houston, London, and Singapore. With revenues of $152 billion in 2016, it is the largest independent energy trader in the world, and would rank eighth on the Fortune Global 500 list. Because Vitol does"
"axigem, Bendacitabin, Biogem, Boligem, Celzar, Citegin, Cytigem, Cytogem, Daplax, DBL, Demozar, Dercin, Emcitab, Enekamub, Eriogem, Fotinex, Gebina, Gemalata, Gembin, Gembine, Gembio, Gemcel, Gemcetin, Gemcibine, Gemcikal, Gemcipen, Gemcired, Gemcirena, Gemcit, Gemcitabin, Gemcitabina, Gemcitabine, Gemcitabinum, Gemcitan, Gemedac, Gemflor, Gemful, Gemita, Gemko, Gemliquid, Gemmis, Gemnil, Gempower, Gemsol, Gemstad, Gemstada, Gemtabine, Gemtavis, Gemtaz, Gemtero, Gemtra, Gemtro, Gemvic, Gemxit, Gemzar, Gentabim, Genuten, Genvir, Geroam, Gestredos, Getanosan, Getmisi, Gezt, Gitrabin, Gramagen, Haxanit, Jemta, Kalbezar, Medigem, Meditabine, Nabigem, Nallian, Oncogem, Oncoril, Pamigeno, Ribozar, Santabin, Sitagem, Symtabin, Yu Jie, Ze Fei, and Zefei. Because it is clinically valuable and is only useful when delivered intravenously, methods to reformulate"
"2014 marketing of Ontak was discontinued in the US. Denileukin diftitox Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these. In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL). There is some evidence tying it to vision loss and in 2006 the FDA added"
"Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a major American manufacturer of diagnostic healthcare products that are sold worldwide. Quidel commenced operations in 1979 and launched its first products in 1984. Quidel Corporation was formed in 1991 when Quidel and Monoclonal Antibodies merged. On June 18, 1997 Quidel settled a lawsuit with Becton Dickinson. Quidel had been accused of infringing patents on Becton's strep and chlamydia products. Quidel agreed to buy a product license and pay royalties on its product sales. In February 2004, Inverness Medical Innovations sued Quidel for patent infringement. That same month, Quidel countersued against Inverness. Since"
"companies on the Standard & Poor's 500. Vertex shares increased 250 percent in the same period. Vertex posted only one annual profit since it was founded in 1989. In May 2011, the Food and Drug Administration (FDA) approved the drug telaprevir (Incivek), an oral treatment for hepatitis C marketed by Vertex. Development and commercialization of telaprevir is shared with Johnson & Johnson for European distribution and Mitsubishi for Asia. Telaprevir is a protease inhibitor. In 2012 ivacaftor, was designated as an orphan drug, identifying cystic fibrosis as affecting fewer than 200,000 people in the United States. On January 31, 2012,"
"Melinta Therapeutics Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut. In mid-2011 Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. It was renamed Melinta Therapeutics in 2013. One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006, was approved by the FDA in 2017. As of 2016 the"
"Ceftiofur Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987. It is marketed by pharmaceutical company Zoetis as Excenel, Naxcel, and Excede and is also the active ingredient in that company's Spectramast LC (lactating cow formulation) and Spectramast DC (dry cow formulation) product. It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against both Gram-positive and Gram-negative bacteria. ""E. coli"" strains resistant to ceftiofur have been reported. The metabolite desfurolyceftiofur also has antibiotic activity. The two compounds are measured together to measure for antibiotic"
"Cedexis, CombineNet, Handango, Host Analytics, HVVi Semiconductors, Liquid Engines, Nextivity, Nominum, Omneon, Packet Design, Qumu, Sanovi, Tripwire, X+1 Cleantech: AltaRock Energy, Coskata, CaliSolar, GreatPoint Energy, Nuventix, Rive Technology, Sub-One Technology, Solar Junction, Wakonda Healthcare: Acceleron, Aperio, Apoptos, Ardian, ConcepTx Medical, Emphasys, EndoGastric Solutions, Five Prime, GI Dynamics, GluMetrics, Gynesonics, Helixis, Hydra BioSciences, NeuroVista, Plexxikon, PolyRemedy, Portola, Powervision, Proteolix, Second Genome, Valeritas, Zeltiq Advanced Technology Ventures Advanced Technology Ventures (ATV) is an American venture capital firm with more than $1.8 billion in capital under management. The firm was founded in 1979 and invests in IT, healthcare, and cleantech companies. ATV has"
"these brand-names: On 19 June 2013, the European Commission imposed a fine of €93.8 million on the Danish pharmaceutical company Lundbeck, plus a total of €52.2 million on several generic pharmaceutical-producing companies. This was in response to Lundbeck entering an agreement with the companies to delay their sales of generic citalopram after Lundbeck's patent on the drug had expired, thus reducing competition in breach of European antitrust law. Citalopram Citalopram (brand names: Celexa, Cipramil and others) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has U.S. Food and Drug Administration approval to treat major depression,"
"publicly traded specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey. In 2014, Pernix became one of the"
"future Janssen Pharmaceuticals, acquired the distribution rights for Gedeon Richter's products. The corporation has two plants today: the headquarters in Budapest, and a subsidiary in Dorog which has been operating since 1967. In October 2010, Gedeon Richter plc acquired 100% of a private Swiss drug company, Preglem, for CHF 445 million (€337 million). The company has joint ventures in India with Themis Medicare, and in Germany, with Helm AG. Gedeon Richter plc Richter Gedeon Nyrt. is a Hungarian multinational pharmaceutical and biotechnology company headquartered in Budapest, Hungary. It is one of the largest companies of the industry in the Central"
"manufactures its products with othercompanies. Achoosom tablets (Diphenhydramine HCl 10 mg) Benzax 0.25/0.5 mg tablets (Alprazolam 0.25 mg and 0.5 mg) Benzax-F tablets (Alprazolam 0.25 mg + Fluoxetine 20 mg) Depresom-ID tablets (Imipramine HCl 25 mg + Diazepam 5 mg) Doxesom tablets (Doxepin HCl 3 mg) Hydrozet-10 tablets (Cetirizine HCl 10 mg) Loresta tablets (Lorazepam 1 mg and 2 mg) Somnotril 0.5 tablets (Clonazepam 0.5 mg) Somnolex tablets (Clonazepam 0.5 mg + Ecitalopram 10 mg) Tophan capsules (Tryptophan 50 mg) Xanfeine tablets (Caffeine 100 mg) Zoltar 5/10 tablets (Zolpidem tartrate 5 mg and 10 mg) Somnogen Canada Inc Somnogen is"
"to a hospital for more accurate testing. In July 2005, a Singapore life science start-up company Veredus Laboratories launched a DNA- and RNA-based diagnostic kits for dengue, avian influenza and malaria. The kit is based on technologies licensed from A*STAR and the National University of Singapore. Another Singapore company Attogenix Biosystems has also developed a biochip called AttoChip which has successfully undergone an independent clinical trial conducted by Tan Tock Seng Hospital and is 98 percent accurate. The AttoChip identifies genes, viruses and bacteria-causing diseases from a blood sample. It can detect the presence of the dengue virus within two"
"on cardiology and diebetology. In 2011, Aarogyam, a specialised division for dermatology products, followed. The Nirog Division was launched in June, 2013 with an investment of Rs 870 million. Deurali-Janta Pharmaceuticals is now one of the largest companies in Nepal. The company plans to export its products to at least five international markets within next 10 years. Deurali-Janta Pharmaceuticals was awarded best pharmaceutical company by Swasthya Khabar Patrika Health Award – 2012. Deurali-Janta Pharmaceuticals Deurali-Janta Pharmaceuticals Private Limited (DJPL) based in Kathmandu, Nepal is one of that country's leading pharmaceutical companies. DJPL manufactures and sells pharmaceutical formulations in Nepal and"
"Fermentek Fermentek Ltd. is a biotechnological company in the Atarot industrial zone of Jerusalem, Israel. It specializes in the research, development and manufacture of biologically active, natural products isolated from microorganisms as well as from other natural sources such as plants and algae. The main microorganisms used are nonpathogenic actinomycetes, Nocardia and Streptomycetes. The fungi used are: Penicillium, Aspergillus, Fusarium and the like. None of these is a human pathogen. Fermentek does not sell to individuals. Most of its products are marketed through major international distributors specializing in chemicals, under their own brand names. Nevertheless, Fermentek has specific impact on"
"HLL Lifecare HLL Lifecare Limited (formerly Hindustan Latex Limited) (HLL) is an Indian healthcare products manufacturing company based in Thiruvananthapuram, Kerala, India. A Government of India-owned corporation (Public-sector undertaking). It produces health care products, including: condoms, contraceptive pills, IUDs, surgical sutures, blood bags and Pharma products . One of HLL's contraceptive products is ormeloxifene, branded as ""Saheli"", the world’s first and only oral non-hormonal, non-steroidal oral contraceptive, taken as a weekly pill. In 2012, HLL announced a polymerase chain reaction based duplex test kit for chikungunya and dengue fever tests in collaboration with the Rajiv Gandhi Centre for Biotechnology, Trivandrum."
"HAL Allergy Group HAL Allergy Group is a pharmaceutical company that develops, produces and sells products for allergy diagnostic and allergen immunotherapy (AIT). The research facilities are located in Leiden Bio Science Park, Netherlands. The focus since 1959 stems from the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. These immunotherapies are used primarily against common allergies such as hay fever, house dust mite allergy and allergic reactions towards wasp or bee stings. With offices in major European countries, HAL Allergy is one of the European top players, particularly in the field of"